ATA polymers of Mr 2,500 are optimally potent inhibitors of vWF-mediated platelet aggregation and may be more effective than commercial ATA mixtures as anti-arterial thrombotic agents.
No takes yet. Share an insight, caveat, or question.
Identifies optimal ATA polymer size for vWF inhibition in preclinical models; leaves open translation to human arterial thrombosis therapy.
Weinstein et al. (1991) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: